Global pharma major Lupin Limited has received approval for its droxidopa capsules, 100 mg, 200 mg, and 300 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Northera capsules, 100 mg, 200 mg, and 300 mg, of Lundbeck NA Ltd.
The product will be manufactured at Lupin’s facility in Nagpur, India.
Droxidopa capsules, 100 mg, 200 mg, and 300 mg, are indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH).
These indications are caused by primary autonomic failure (Parkinson’s disease, multiple system atrophy, and pure autonomic failure), dopamine beta- hydroxylase deficiency, and non-diabetic autonomic neuropathy.
Droxidopa capsules had estimated annual sales of US$352 million in the US, according to IQVIA MAT December 2020.
Go to main website, click here
Subscribe for daily free updates, click here
For daily free updates on WhatsApp, click here